CL2011001073A1 - Compuestos derivados de 1-[{pirrolidin-3-il}-carbonil]-5-(piperazin-1-ilcarbonil)-pirrolidin, agonistas de los receptores de la melanocortina; composicion farmaceutica; utiles en el tratamiento de la obesidad, diabetes, inflamacion y disfusion erectil. - Google Patents

Compuestos derivados de 1-[{pirrolidin-3-il}-carbonil]-5-(piperazin-1-ilcarbonil)-pirrolidin, agonistas de los receptores de la melanocortina; composicion farmaceutica; utiles en el tratamiento de la obesidad, diabetes, inflamacion y disfusion erectil.

Info

Publication number
CL2011001073A1
CL2011001073A1 CL2011001073A CL2011001073A CL2011001073A1 CL 2011001073 A1 CL2011001073 A1 CL 2011001073A1 CL 2011001073 A CL2011001073 A CL 2011001073A CL 2011001073 A CL2011001073 A CL 2011001073A CL 2011001073 A1 CL2011001073 A1 CL 2011001073A1
Authority
CL
Chile
Prior art keywords
obesity
diabetes
inflammation
treatment
pharmaceutical composition
Prior art date
Application number
CL2011001073A
Other languages
English (en)
Inventor
Koo Lee
Sang Dae Lee
Sang Pil Moon
In Ae Ahn
Sung Pil Choi
Hyun Ho Lee
Dong Sup Shim
Soo Yong Chung
Hyun Min Lee
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of CL2011001073A1 publication Critical patent/CL2011001073A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Compuestos heterocíclicos agonistas de receptores de melanocortina; composición farmacéutica que los comprende; su uso en la prevención y el tratamiento de obesidad, diabetes, inflamación y disfunción eréctil.
CL2011001073A 2008-11-12 2011-05-12 Compuestos derivados de 1-[{pirrolidin-3-il}-carbonil]-5-(piperazin-1-ilcarbonil)-pirrolidin, agonistas de los receptores de la melanocortina; composicion farmaceutica; utiles en el tratamiento de la obesidad, diabetes, inflamacion y disfusion erectil. CL2011001073A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20080112403 2008-11-12

Publications (1)

Publication Number Publication Date
CL2011001073A1 true CL2011001073A1 (es) 2011-10-07

Family

ID=42165801

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011001073A CL2011001073A1 (es) 2008-11-12 2011-05-12 Compuestos derivados de 1-[{pirrolidin-3-il}-carbonil]-5-(piperazin-1-ilcarbonil)-pirrolidin, agonistas de los receptores de la melanocortina; composicion farmaceutica; utiles en el tratamiento de la obesidad, diabetes, inflamacion y disfusion erectil.

Country Status (26)

Country Link
US (4) US8039622B2 (es)
EP (1) EP2350060B1 (es)
JP (1) JP5399506B2 (es)
KR (1) KR101141976B1 (es)
CN (1) CN102282141B (es)
AR (1) AR074109A1 (es)
AU (1) AU2009314827B2 (es)
BR (1) BRPI0921063B8 (es)
CA (1) CA2742248C (es)
CL (1) CL2011001073A1 (es)
CO (1) CO6362006A2 (es)
CR (1) CR20110250A (es)
EA (1) EA019146B1 (es)
EC (1) ECSP11011026A (es)
GE (1) GEP20135850B (es)
IL (1) IL212468A0 (es)
MA (1) MA32774B1 (es)
MX (1) MX2011004583A (es)
NZ (1) NZ592512A (es)
PE (1) PE20110684A1 (es)
TN (1) TN2011000222A1 (es)
TW (1) TWI389903B (es)
UA (1) UA99555C2 (es)
UY (1) UY32238A (es)
WO (1) WO2010056022A2 (es)
ZA (1) ZA201103154B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99555C2 (en) * 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
WO2012100342A1 (en) 2011-01-27 2012-08-02 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
CA2862444A1 (en) 2011-12-29 2013-07-04 Rhythm Metabolic, Inc. Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
RU2014145806A (ru) 2012-04-25 2016-06-10 Ф. Хоффманн-Ля Рош Аг Способы производства (3,4-дихлорфенил)-((s)-3-пропил-пирролидин-3-ил)-метанонгидрохлорида
CN103420981A (zh) * 2012-05-21 2013-12-04 中国医学科学院药物研究所 含有取代吡咯烷基的硫代吗啉类化合物
MA43040A (fr) 2015-09-30 2018-08-08 Univ Berlin Charite Méthode de traitement de troubles associés à la voie du récepteur de la mélanocortine 4
EP3773897A1 (en) 2018-04-06 2021-02-17 Rhythm Pharmaceuticals, Inc. Compositions for treating kidney disease
EP3953327B1 (en) * 2019-11-07 2023-12-27 Lg Chem, Ltd. Melanocortin-4 receptor agonists
JP2023548162A (ja) * 2020-10-29 2023-11-15 エルジー・ケム・リミテッド 無定形のメラノコルチン－４受容体アゴニスト
CN116507614A (zh) 2020-10-29 2023-07-28 株式会社Lg化学 黑皮质素受体激动剂化合物的晶型iv及其制备方法
CA3195298A1 (en) 2020-10-29 2022-05-05 Lg Chem, Ltd. Crystalline form i of melanocortin receptor agonist compound and preparation method therefor
EP4219474A4 (en) 2020-10-29 2024-03-13 Lg Chem, Ltd. Crystalline form iii of melanocortin receptor agonist compound and method for preparing same
EP4219473A4 (en) * 2020-10-29 2024-03-13 Lg Chem, Ltd. CRYSTAL TYPE II OF A MALANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD FOR THE PRODUCTION THEREOF
TWI832128B (zh) * 2020-12-22 2024-02-11 南韓商Ｌｇ化學股份有限公司 使用作為黑皮質素-4受體選擇性促效劑
US20240051919A1 (en) * 2020-12-22 2024-02-15 Lg Chem, Ltd. Crystalline form iii of melanocortin receptor agonist compound and preparation method therefor
CN116648249A (zh) 2020-12-22 2023-08-25 株式会社Lg化学 黑皮质素受体激动剂化合物的结晶形式ii及其制备方法
JP2024500966A (ja) * 2020-12-22 2024-01-10 エルジー・ケム・リミテッド メラノコルチン受容体アゴニスト化合物の結晶形ｉおよびその製造方法
WO2022139441A1 (ko) * 2020-12-22 2022-06-30 주식회사 엘지화학 무정형의 멜라노코르틴 수용체 작용제 및 이의 제조방법
AU2022209657B2 (en) * 2021-01-21 2025-06-05 Lg Chem, Ltd. Uses of melanocortin-4 receptor agonist
EP4299572A4 (en) * 2021-02-26 2024-07-31 Lg Chem, Ltd. MELANOCORTIN RECEPTOR 4 AGONIST
US20240228473A1 (en) 2021-05-06 2024-07-11 Lg Chem, Ltd. Crystalline form v of melanocortin receptor agonist compound, and method for preparing same
US20240239783A1 (en) * 2021-05-06 2024-07-18 Lg Chem, Ltd. Crystal form vii of melanocortin receptor agonist compound and method for preparing same
AU2022271120A1 (en) * 2021-05-07 2023-11-09 Lg Chem, Ltd. Crystal form iv of organic acid salts of melanocortin receptor agonist compound, and preparation method thereof
CN117242063A (zh) 2021-05-07 2023-12-15 株式会社Lg化学 黑皮质素受体激动剂化合物与香兰素的共晶及其制备方法
BR112023022334A2 (pt) 2021-05-07 2023-12-26 Lg Chemical Ltd Formas cristalinas de sulfato do composto agonista do receptor de melanocortina, seus métodos de preparação, seus usos, e composições farmacêuticas compreendendo as mesmas

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534503B1 (en) * 1998-04-28 2003-03-18 Lion Bioscience Ag Melanocortin receptor-3 ligands to treat sexual dysfunction
WO2000074679A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
GB0002059D0 (en) 2000-01-28 2000-03-22 Melacure Therapeutics Ab Novel aromatic amines
EP1268000A4 (en) 2000-03-23 2004-12-29 Merck & Co Inc SPIROPIPERID DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS
AU4929601A (en) 2000-03-23 2001-10-03 Merck & Co Inc Substituted piperidines as melanocortin receptor agonists
GB0019359D0 (en) * 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
AU2001288285B2 (en) 2000-08-23 2005-09-29 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
DZ3415A1 (fr) 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
WO2002059117A1 (en) 2001-01-23 2002-08-01 Eli Lilly And Company Piperazine- and piperidine-derivatives as melanocortin receptor agonists
WO2002059107A1 (en) 2001-01-23 2002-08-01 Eli Lilly And Company Substituted piperidines/piperazines as melanocortin receptor agonists
US7169777B2 (en) 2001-01-23 2007-01-30 Eli Lilly And Company Melanocortin receptor agonists
DE60215132T2 (de) 2001-02-28 2007-08-23 Merck & Co., Inc. Acylierte piperidin-derivate als melanocortin-4-rezeptor-agonisten
ATE430565T1 (de) 2001-02-28 2009-05-15 Merck & Co Inc Acylierte piperidinderivate als melanocortin-4- rezeptoragonisten
IL157253A0 (en) 2001-02-28 2004-02-19 Merck & Co Inc Acylated piperidine derivatives as melanocortin-4 receptor agonists
ATE348097T1 (de) 2001-04-09 2007-01-15 Chiron Corp Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten
US6911447B2 (en) 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
WO2004078717A1 (en) 2003-03-03 2004-09-16 Merck & Co., Inc. Acylated piperazine derivatives as melanocortin-4 receptor agonists
CA2519939A1 (en) 2003-03-26 2004-10-14 Merck & Co., Inc. Bicyclic piperidine derivatives as melanocortin-4 receptor agonists
US20050192286A1 (en) 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
US7989634B2 (en) * 2003-11-12 2011-08-02 Lg Life Sciences Ltd. Melanocortin receptor agonists
GB0402492D0 (en) 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
JP2008506696A (ja) 2004-07-16 2008-03-06 メルク　エンド　カムパニー　インコーポレーテッド メラノコルチン−４受容体作用薬としてのアシル化ピペリジン誘導体
EP1773338B1 (en) 2004-07-19 2010-01-06 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
DE102005000666B3 (de) 2005-01-04 2006-10-05 Sanofi-Aventis Deutschland Gmbh Sulfonylpyrrolidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP2009503048A (ja) 2005-08-01 2009-01-29 ファイザー・リミテッド 尿路機能障害を治療するためのｍｃ４ｒ作動薬
WO2007015162A1 (en) 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
AU2006297452A1 (en) 2005-09-30 2007-04-12 Merck Sharp & Dohme Corp. Acylated piperidine derivatives as melanocortin-4 receptor agonists
EP1940401B1 (en) 2005-10-18 2012-07-11 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
JP2007131570A (ja) 2005-11-09 2007-05-31 Mitsubishi Pharma Corp 新規なアミノピロリジン誘導体
ES2402581T3 (es) 2006-02-23 2013-05-06 Pfizer Limited Piperidinoilpirrolidinas como agonistas del receptor de melanocortina tipo 4
WO2007096186A1 (en) 2006-02-23 2007-08-30 Santhera Pharmaceuticals (Schweiz) Ag Substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators
EP2035373B1 (en) 2006-06-09 2011-05-04 Action Pharma A/S Phenyl pyrrole aminoguanidine derivatives
TWI332501B (en) 2006-07-14 2010-11-01 Lg Life Sciences Ltd Melanocortin receptor agonists
US20090253744A1 (en) 2006-09-27 2009-10-08 Bakshi Raman K Acylated piperidine derivatives as melanocortin-4 receptor modulators
UA99555C2 (en) * 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists

Also Published As

Publication number Publication date
GEP20135850B (en) 2013-06-10
BRPI0921063B8 (pt) 2021-05-25
EA019146B1 (ru) 2014-01-30
CA2742248C (en) 2014-01-14
TWI389903B (zh) 2013-03-21
MA32774B1 (fr) 2011-11-01
ECSP11011026A (es) 2011-06-30
CN102282141B (zh) 2014-09-10
CN102282141A (zh) 2011-12-14
KR101141976B1 (ko) 2012-05-07
JP5399506B2 (ja) 2014-01-29
EP2350060B1 (en) 2013-09-18
EP2350060A4 (en) 2012-07-25
US8288386B2 (en) 2012-10-16
WO2010056022A2 (en) 2010-05-20
ZA201103154B (en) 2012-01-25
CA2742248A1 (en) 2010-05-20
KR20100053458A (ko) 2010-05-20
US8183243B2 (en) 2012-05-22
IL212468A0 (en) 2011-06-30
UA99555C2 (en) 2012-08-27
NZ592512A (en) 2012-12-21
JP2012508730A (ja) 2012-04-12
BRPI0921063B1 (pt) 2021-03-16
PE20110684A1 (es) 2011-09-28
WO2010056022A3 (en) 2010-09-10
TN2011000222A1 (en) 2012-12-17
US20110224219A1 (en) 2011-09-15
UY32238A (es) 2010-01-05
EP2350060A2 (en) 2011-08-03
US8039622B2 (en) 2011-10-18
US20100120783A1 (en) 2010-05-13
US20110237795A1 (en) 2011-09-29
TW201022246A (en) 2010-06-16
CR20110250A (es) 2011-08-26
EA201170676A1 (ru) 2011-12-30
CO6362006A2 (es) 2012-01-20
MX2011004583A (es) 2011-06-01
AR074109A1 (es) 2010-12-22
US8236955B2 (en) 2012-08-07
AU2009314827A1 (en) 2010-05-20
BRPI0921063A2 (pt) 2015-08-25
US20110245500A1 (en) 2011-10-06
AU2009314827B2 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
CL2011001073A1 (es) Compuestos derivados de 1-[{pirrolidin-3-il}-carbonil]-5-(piperazin-1-ilcarbonil)-pirrolidin, agonistas de los receptores de la melanocortina; composicion farmaceutica; utiles en el tratamiento de la obesidad, diabetes, inflamacion y disfusion erectil.
CL2008003847A1 (es) Compuestos derivados de 6-fenilpirazin-2-carboxamida y 6-fenilpirazin-2-carbotioamida, inhibidores de dgat-1; composicion farmaceutica; y su uso en el tratamiento de la diabetes mellitus y obesidad.
CL2011000851A1 (es) Composicion farmaceutica que comprende al menos una insulina y al menos un agonista de glp-1; metodo de preparacion; su uso para tratar diabetes o prevenir la disfuncion de celulas beta pancreaticas; kit; y dispositivo.
CL2009000873A1 (es) Compuestos derivados de ciclohepta[b]piridina, antagonistas del receptor de cgrp; composicion farmaceutica; y uso para el tratamiento de la migrana.b
MY151568A (en) Cyclohexyl amide derivatives and their use as crf-1 receptor antagonists
CL2011003085A1 (es) Compuestos derivados de 1-(piperidin-4-il)-pirazol, moduladores de la actividad del receptor acoplado a proteina g, gpr 119; composicion farmaceutica; uso de los compuestos en el tratamiento de la diabetes o de una morbilidad asociada con dicha diabetes.
CL2011000051A1 (es) Compuestos derivados de piperidinilo, agonistas del receptor acoplado a la proteina g; composicion farmaceutica que los comprende; y su uso para la regulacion de la saciedad, tratar la obesidad, diabetes, sindrome metabolico, intolerancia ala glucosa, hiperlipidemias o hipertension, entre otras enfermedades.
CL2011000501A1 (es) Composición farmacéutica que comprende un agonista de gpr119 en combinación con un inhibidor de dpp-4 seleccionado de un grupo definido; uso para prevenir y/o tratar enfermedades metabólicas, como resistencia insulinica, diabetes, sindrome metabolico, obesidad, hiperlipidemia, osteoporosis, entre otras.
ECSP12011606A (es) Agonistas de gpr119
CL2011001333A1 (es) Compuestos derivados de heterociclos nitrogenados sustituidos, inhibidores de ns5a; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2007002296A1 (es) Compuestos derivados de imidazolina-2,4-dionas sustituidas con arilaminoalquilo; composicion farmaceutica; y uso del compuesto en el tratamiento del sindrome metabolico, diabetes, obesidad, dependencia de la nicotina, dependencia del alcohol, trastor
CL2008000985A1 (es) Compuesto derivado de heterociclos de nitrogeno, agonistas del receptor gnrh; composicion farmaceutica que comprende a dicho compuesto; y uso para tratar una afeccion relacionada con las hormonas sexuales, endometriosis, dismenorrea, enfermedad de ov
CL2009000171A1 (es) Compuestos derivados de 1-oxa-3-azaespiro, antagonistas del receptor y5 de neuropeptido y (npy); composicion farmaceutica que comprende dicho compuesto; y uso para el tratamiento de trastornos de la alimentacion, trastornos de la bebida, obesidad y depresion.
CL2011000087A1 (es) Compuestos derivados de heteroarilo sustituido, inhibidores de los receptores dgat1; composicion farmaceutica; y su uso para tratar la diabetes tipo ll y obesidad.
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2009000368A1 (es) 3-(amido o sulfamido)-4-(4-azinil sustituido) benzamidas o benzosulfonamidas; la composicion farmaceutica que los contiene; el uso de los compuestos; y un kit que contiene dichos compeustos; utiles como inhibidores del receptor de quimioquinas cxcr3.
CL2007003266A1 (es) Compuestos derivados de progesterona, antagonistas del receptor de progesterona; composicion farmaceutica; y uso para el tratamiento de endometriosis, miomas o tumores dependientes de hormonas.
CL2011002036A1 (es) Analogo peptidico doble agonista de los receptores de glp-1 y de glucagon.
CL2012000702A1 (es) Uso de un agonista del receptor de acetilcolina nicotinico alfa-7 para el tratamiento de la discinesia asociada a la terapia con agonista de dopamina en la enfermedad de parkinson.
ATE516300T1 (de) Neuromedin-u-rezeptoragonisten und ihre verwendung
CL2008001049A1 (es) Compuestos derivados de benzamidas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, intolerancia a la glucosa, dislipidemia, hipertension, obesidad.
CL2007002167A1 (es) Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
CL2007003552A1 (es) Compuestos derivados de pirimidina y piridina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un trastorno proliferativo celular.
CL2011002182A1 (es) Compuestos heterociclicos que contienen 2 o mas heterociclos con n como heteroatomos del ciclo, agonistas de gpr119 e inhibidores de dpp-iv; composicion farmaceutica; y su uso en el tratamiento de la diabetes tipo ii, obesidad, sindrome metabolico, tolerancia deteriorada a la glucosa e hiperlipidemia, entre otras enfermedades..